Trial Profile

A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos [pioglitazone] in Patients With Type 2 Diabetes and NYHA [New York Heart Association] Class II Heart Failure.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Apr 2008 Status changed from in progress to completed, according to Roche site
23 Jan 2008 Updated from Roche site (DMS 23-01-08).
23 Jan 2008 Status changed from recruiting to in progress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com